Epigenetics Drugs and Diagnostic Technologies Market, by Type

Epigenetics Drugs and Diagnostic Technologies Market is estimated to be valued at USD 18.81 Bn in 2026 and is expected to reach USD 63.58 Bn by 2033, growing at a compound annual growth rate (CAGR) of 19.0% from 2026 to 2033.

Gene mutations often result in the disruption of normal processing of genes and leads to the development of diseases. However, recently discovered epigenetic alterations have shown the potential to greatly influence tumoral response to therapy regimens. Such epigenetic alterations have proven to be dynamic, and thus could be restored. Due to their reversible nature, the promising opportunity to improve chemotherapy response using epigenetic therapy has arisen. Potential epidrug candidates can be found through a process known as drug repositioning or repurposing, a promising strategy for the discovery of novel potential targets in already approved drugs. At present, novel epidrug candidates have been identified in preclinical studies and some others are currently being tested in clinical trials, ready to be repositioned. The main focus of epidrug repurposing is the development of agents with one indication only, while giving patients lower cost therapies and a novel precision medical approach to optimize treatment efficacy and reduce toxicity. Epigenetic drugs are commonly used in the treatment of infections, cancer, diabetic retinopathy, cardiac dysfunction, schizophrenia, and mental problems including posttraumatic stress disorder. They are categorized into four classes: hydroxamates (vorinostat, belinostat, panobinostat), benzamides (entinostat, chidamide), cyclic peptides (romidepsin), and aliphatic acids.

Market Dynamics

Increasing new product launches, and mergers and acquisitions by key market players is expected to drive the global epigenetics drugs & diagnostic technologies market growth. For instance, on November 4, 2021, Epizyme, Inc., a U.S. based clinical-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EZM0414, the company's novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). The company has also initiated a Phase 1/1b study to evaluate safety and determine the optimal dose of EZM0414.

Key features of the study:

• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market

Detailed Segmentation:

• Global Epigenetics Drugs and Diagnostic Technologies Market, By Type (Revenue, USD Bn, 2021 - 2033)
• Epigenetic Drugs
  • DNMT Inhibitors
    • Azacitidine
    • Decitabine
  • HDAC Inhibitors
    • Vorinostat
    • Romidepsin
  • Others
• Epigenetics Diagnostic Technologies
  • DNAMethylation
  • CHIP Technology
• Global Epigenetics Drugs and Diagnostic Technologies Market, By Region (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Regenacy Pharmaceuticals, Inc.
• Astex Pharmaceuticals
• 4SC AG
• CellCentric Ltd.
• Celleron Therapeutics Ltd.
• Bristol-Myers Squibb Company
• Oryzon Genomics S.A.
• ChromaMedicine, Inc.
• Epizyme, Inc.
• EpiGentek Group Inc.